Over the past five decades, the UAE has transformed from an oil-centric economy to a global centre for innovation. For more than twenty years, Mubadala has played a pivotal role within this, helping advance the UAE’s innovation economy, to drive sustainable growth for the benefit of current and future generations.

As the country continues its economic diversification and global integration, biopharma has become central to its vision for a sustainable healthcare ecosystem. The UAE’s leadership has identified life sciences and biopharma as key sectors within the Abu Dhabi Vision 2030, and government-led efforts over the last decade have propelled substantial growth, enabling the UAE to lead the region in advanced healthcare.

Reflecting this commitment, 7.6 percent of the UAE’s Federal General Budget for 2023-2026 is allocated to supporting initiatives that foster an environment where innovation can thrive. These investments help attract foreign direct investment, talent, and expertise into the UAE, with public-private partnerships strengthening the region’s healthcare infrastructure and reputation for quality, patient-centric care.

Building on this momentum, Mubadala is actively developing a robust biopharma ecosystem in Abu Dhabi. Our strategic investments support the infrastructure needed for a resilient sector - establishing essential facilities, such as warehousing and cold storage, and driving advancements in pharmaceutical R&D and manufacturing. From partnerships with research institutions and digital health platforms to a pharmaceutical air hub and biopharma-specific infrastructure, our work is paving the way for a complete biopharma value chain within the UAE.

A notable example is the Kizad Life Sciences Park, which will soon host the UAE’s first Goods Manufacturing Practice (GMP) biopharma facility. This advanced facility, the first-of-its-kind in the region, will enable the UAE to manufacture critical life sciences products locally and support future innovation in biologics.

Mubadala also supports initiatives like the Emirati Genome Programme, which is helping researchers identify genetic markers tied to complex diseases, enabling better-targeted treatments and drug development. Additionally, clinical trials in Abu Dhabi have increased by 484 percent in recent years, covering fields such as neurology, oncology, and cardiology, as the Department of Health accelerates trial approvals to meet the needs of the UAE’s growing population.

Mubadala is at the forefront of responsible capital deployment across advanced industries. We are committed to building a sustainable biopharma sector that addresses the regions health needs, helping create a future in which groundbreaking treatments and technologies are readily accessible to all.